ClinicalTrials.gg
TerminatedNCT03942601TAP-DANCEUpdated Jul 10, 2024

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

A Phase 2 interventional study of Temsirolimus and Temsirolimus and dexamethasone sodium phosphate in Peripheral Arterial Disease, sponsored by Mercator MedSystems, Inc.. Terminated at 11 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by Mercator MedSystems, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Halted due to pandemic.

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Enrollment
328th of 373
10 · median 64
Started
2019
with 23 others
Phase 2
48 of 479
4 open now
Registered
302nd of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 328th largest by enrollment of the 373 interventional ones that give a count, is one of 24 that started in 2019, is one of 48 in phase 2, and was the 302nd registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, pilot feasibility study to document the effects of adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate injection, USP, after revascularization of femoropopliteal lesions in symptomatic patients with moderate to severe claudication (Rutherford 2-3) or critical limb ischemia (CLI) with rest pain (Rutherford 4). Subjects will be followed for up to 60 months post index procedure.

Read the detailed description

To begin to assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial deposition of temsirolimus or temsirolimus with dexamethasone in maintaining luminal patency and composite safety endpoints in patients with clinical evidence of moderate to severe claudication or critical limb ischemia with rest pain after revascularization of one or more angiographically significant lesion(s) in superficial femoral or popliteal arteries.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤85 years at study enrollment
  • Subject has been informed of the nature of the study, agrees to participate and has signed an IRB-approved consent form
  • Subject is ambulatory
  • Female subjects of have a negative pregnancy test ≤7 days before the procedure and are willing to use a highly effective method of (See Section 12.2) for one month preceding and 12 months following study treatment
  • Subject has documented moderate to severe claudication (Rutherford 2-3) or Critical Limb Ischemia (CLI) with rest pain (Rutherford 4) in the target limb due to arterial stenosis within the superficial femoral and/or popliteal artery
  • >2 years in the Investigator's opinion Angiographic Criteria (Target Lesion Definition)
  • Target vessel reference diameter ≥3 mm and ≤8 mm
  • Single or multiple de novo atherosclerotic or restenotic lesion(s) with ≥70% narrowing in the superficial femoral or popliteal artery meeting the following criteria:

    • The target lesion must be ≤20 cm in total length
    • The target lesion does not have more than 5 cm of contiguous length of intervening normal artery
    • The target lesion does not cross into the common femoral artery or tibeoperoneal trunk
    • The target lesion is located at least 10 mm away from any previously placed stent or graft
  • Successful wire crossing (sub-intimal is allowed) and revascularization by balloon angioplasty of the target lesion with less than 30% residual stenosis and run-off in at least one patent vessel into the foot

Exclusion criteria

Exclusion Screening Criteria:

  • Subject is already enrolled in another clinical study of systemic drug therapy or another device study that has not completed its primary endpoint
  • Subject unwilling or unlikely to comply with visit schedule
  • Subjects who are incapable of providing consent and/or incapable of understanding the nature, significance and implications of the clinical trial
  • Subject is already receiving, has received in prior 2 months, or is planned in the 6 months after index procedure to receive systemic immunotherapy, chemotherapy, or systemic (however, steroid pre-treatment for contrast allergy, inhaled steroids for asthma treatment or topical steroid uses are allowed)
  • Subject is receiving chronic anticoagulation therapy e.g. warfarin (note: chronic antiplatelet therapy, e.g. aspirin and clopidigrel, and procedural anticoagulation therapy, e.g. heparin or bivalirudin, are allowed)
  • Subject has a level of >1.5xULN
  • Recent (\<30 days prior to study procedure) myocardial infarction
  • Cerebrovascular accident \<60 days prior to the study procedure or any history of intracerebral hemorrhage
  • Any surgical or endovascular procedure (not including staged revascularization in the target limb, e.g. inflow revascularization prior to index procedure or below-knee revascularization after the index procedure) performed within 14 days prior to the index procedure or planned within 30 days post index procedure
  • Planned amputation in the target limb
  • Active foot infection or ischemic foot wound
  • Inability to receive temsirolimus, dexamethasone or iodinated contrast medium due to labeled or known sensitivity reactions
  • Estimated (eGFR, calculated from serum creatinine using an isotope dilution mass spectrometry (IDMS)-traceable equation) less than 30 mL/min Angiographic/Procedural Criteria
  • Hemodynamically significant inflow lesion (≥50% DS) or occlusion in the ipsilateral iliac artery in which there is failure to successfully treat and obtain a \<30% residual stenosis post-revascularization, with bailout stenting as needed (in-flow lesions should be treated prior to treating the target lesion)
  • Prior stent placement in target lesion (i.e., in-stent restenosis)
  • Target lesion restenosis of any kind within 6 months of a prior intervention
  • Use of alternative therapy, e.g. radiation therapy, drug-eluting stents (DES) or drug-eluting balloon/drug-coated balloons (DEB/DCB) as part of the target lesion treatment during the index procedure or during the previous 12 months
  • Use of atherectomy devices in the target lesion during the index procedure
  • Aneurysm in the target vessel
  • Acute thrombus in the target limb
  • Heavy eccentric or concentric calcification at target lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Device needle through the vessel wall
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    Group 1 - temsirolimus injection

    Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1

    Drug: Temsirolimus

  • Active comparator
    Group 2 - temsirolimus and dexamethasone injection

    Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2

    Drug: Temsirolimus and dexamethasone sodium phosphate

Interventions

  • Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1

  • DrugTemsirolimus and dexamethasone sodium phosphate

    Drug pages: Temsirolimus · Dexamethasone phosphate

    Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2

06

What researchers measure

Primary outcomes

  1. Safety - Freedom from MALE-POD at 30 days

    Freedom from MALE-POD at 30 days

    Time frame: 30 days post intervention

  2. Effectiveness - Primary patency

    Primary patency (adjudicate by angio core lab)

    Time frame: 12 months post intervention

  3. Effectiveness - Freedom from CD-TLR

    Freedom from clinically driven target lesion revascularization (CD-TLR)) at 12 months.

    Time frame: 12 months post intervention

07

Study locations

11 sites
  • Arkansas Heart Hospital
    Little Rock, Arkansas 72211, United States
  • St. Joseph Hospital of Orange Heart and Vascular Center
    Orange, California 92868, United States
  • San Francisco VA Medical Center
    San Francisco, California 94121, United States
  • University of Colorado
    Denver, Colorado 80045, United States
  • Rocky Mountain Veterans Administration Hospital
    Denver, Colorado 80220, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • Columbia University Medical Center/NYPH
    New York, New York 10032, United States
  • North Carolina Heart and Vascular
    Raleigh, North Carolina 27607, United States
  • University Hospital
    Cleveland, Ohio 44106, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Apr 2021, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 8, 2019
StartActual
Oct 1, 2019
Primary completionActual
Apr 30, 2021
CompletionActual
Apr 30, 2021
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03942601
Lead sponsor
Mercator MedSystems, Inc.
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Oct 1, 2019
Primary completion
Apr 30, 2021
Completion
Apr 30, 2021
Last update
Jul 10, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Temsirolimus · Dexamethasone phosphate

Start the discussion